Top-Rated StocksTop-RatedNASDAQ:RCKT Rocket Pharmaceuticals (RCKT) Stock Forecast, Price & News $24.95 +1.49 (+6.35%) (As of 09:01 AM ET) Add Compare Share Share Today's Range$24.95▼$24.9550-Day Range$16.59▼$23.4652-Week Range$9.50▼$24.95Volume2,106 shsAverage Volume777,963 shsMarket Capitalization$2.01 billionP/E RatioN/ADividend YieldN/APrice Target$51.09 ProfileProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsShort InterestSocial MediaSustainabilityProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsShort InterestSocial MediaSustainability Rocket Pharmaceuticals MarketRank™ ForecastAnalyst RatingBuy3.00 Rating ScoreUpside/Downside104.8% Upside$51.09 Price TargetShort InterestBearish10.07% of Shares Sold ShortDividend StrengthN/ASustainability-0.81Upright™ Environmental ScoreNews Sentiment0.43Based on 17 Articles This WeekInsider TradingSelling Shares$43,678 Sold Last QuarterProj. Earnings GrowthGrowingFrom ($3.08) to ($2.12) Per ShareSee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.2.35 out of 5 starsMedical Sector196th out of 986 stocksPharmaceutical Preparations Industry87th out of 486 stocks 3.5 Analyst's Opinion Consensus RatingRocket Pharmaceuticals has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 12 buy ratings, no hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $51.09, Rocket Pharmaceuticals has a forecasted upside of 104.8% from its current price of $24.95.Amount of Analyst CoverageRocket Pharmaceuticals has only been the subject of 2 research reports in the past 90 days. Previous Next 1.0 Short Interest Percentage of Shares Shorted10.07% of the outstanding shares of Rocket Pharmaceuticals have been sold short.Short Interest Ratio / Days to CoverRocket Pharmaceuticals has a short interest ratio ("days to cover") of 9.8.Change versus previous monthShort interest in Rocket Pharmaceuticals has recently increased by 0.87%, indicating that investor sentiment is decreasing. Previous Next 0.0 Dividend Strength Dividend YieldRocket Pharmaceuticals does not currently pay a dividend.Dividend GrowthRocket Pharmaceuticals does not have a long track record of dividend growth. Previous Next 4.7 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreRocket Pharmaceuticals has received a 74.90% net impact score from Upright. The largest positive contribution comes from its "Physical diseases" impact, which is driven by its "Clinical research services for physical health" and "Preclinical research services for physical health" products. See details.Environmental SustainabilityThe Environmental Impact score for Rocket Pharmaceuticals is -0.81. Previous Next 1.9 News and Social Media Coverage News SentimentRocket Pharmaceuticals has a news sentiment score of 0.43. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.News Coverage This WeekMarketBeat has tracked 17 news articles for Rocket Pharmaceuticals this week, compared to 8 articles on an average week.Search InterestOnly 15 people have searched for RCKT on MarketBeat in the last 30 days. This is a decrease of -55% compared to the previous 30 days.MarketBeat FollowsOnly 3 people have added Rocket Pharmaceuticals to their MarketBeat watchlist in the last 30 days. This is a decrease of -67% compared to the previous 30 days. Previous Next 4.2 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Rocket Pharmaceuticals insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $43,678.00 in company stock.Percentage Held by Insiders31.10% of the stock of Rocket Pharmaceuticals is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions93.23% of the stock of Rocket Pharmaceuticals is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Rocket Pharmaceuticals are expected to grow in the coming year, from ($3.08) to ($2.12) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Rocket Pharmaceuticals is -7.45, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Rocket Pharmaceuticals is -7.45, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioRocket Pharmaceuticals has a P/B Ratio of 3.86. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here About Rocket Pharmaceuticals (NASDAQ:RCKT) StockRocket Pharmaceuticals, Inc. is a clinical-stage biotechnology company, which engages in the development of gene therapy treatment options for rare and devastating pediatric diseases. Its multi-platform development approach applies the lentiviral vector and adeno-associated viral vector gene therapy platforms. Its clinical program is an LVV-based gene therapy for the treatment of Fanconi Anemia (FA), a difficult to treat genetic disease that leads to bone marrow failure and potentially cancer. The company was founded on July 7, 1999 and is headquartered in Cranbury, NJ.Read More Receive RCKT Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Rocket Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Email Address RCKT Stock News HeadlinesJune 8, 2023 | msn.comSabrent Rocket Q4 NVMe SSD review: Uncommonly small, shockingly powerfulJune 8, 2023 | msn.comFive golfers with Michigan ties to play for spot in $8.8-million Rocket Mortgage ClassicJune 9, 2023 | Edge On The Street (Ad)All Electric Commitment From GM, Volkswagen, Could Put Lithium Sector In A SupercycleMore automakers are pledging to go "fully electric" by 2035. NOW is the perfect time to get in on the "EV Revolution." And the best way to potentially do that, is to skip over the overvalued electric vehicle stocks...June 8, 2023 | msn.comRocket Pharma wins key FDA designations for heart disease candidateJune 8, 2023 | detroitnews.comHere's who's teeing it up at the 2023 Rocket Mortgage ClassicJune 8, 2023 | markets.businessinsider.comRocket Pharma Says FDA Grants Fast Track And Orphan Drug Designations For RP-A601 Gene TherapyJune 8, 2023 | finance.yahoo.comRocket Pharmaceuticals Receives FDA Fast Track and Orphan Drug Designations for RP-A601 Gene Therapy for PKP2 Arrhythmogenic Cardiomyopathy (ACM)June 7, 2023 | detroitnews.comJustin Thomas, one of golf's biggest stars, will play Rocket Mortgage Classic for 1st timeJune 9, 2023 | Edge On The Street (Ad)Graphite versus Lithium - What Investors Should KnowOver 18 million EVs will be cruising U.S roads by 2030. And every one million EVs manufactured will require 82,000 tons of the metal graphite for their batteries. That's a total of 1,476,000 tons of graphite! Graphite is actually the largest component of EV batteries - NOT lithium. Experts warn of a massive graphite shortfall, especially since North America currently has no operating graphite mines.June 7, 2023 | detroitnews.comA look at DGC's vandalized greens with the Rocket Mortgage Classic loomingJune 6, 2023 | msn.comRocket League Season 11 Update: Release Date & Start TimeJune 6, 2023 | americanbankingnews.comBrokerages Set Rocket Pharmaceuticals, Inc. (NASDAQ:RCKT) PT at $51.09June 5, 2023 | detroitnews.comMajor winner, Netflix darling among latest commitments to Rocket Mortgage ClassicJune 5, 2023 | detroitnews.comFinau credits Rocket Mortgage Classic for helping catapult his careerJune 5, 2023 | msn.comJoJo Siwa Lets Her 'Inner Elton' Out in Support of Elton John's New Rocket Fund: 'Such a Beautiful Thing' (Exclusive)June 3, 2023 | bbc.comRocket League: Exeter-based IT firm Timewade wins esports eventJune 2, 2023 | fxstreet.comRPL price coils up for a breakout fueled by a 70% rise in Rocket Pool network growthJune 2, 2023 | fxstreet.comLido Finance, Rocket Pool tokens rally as traders stake $180 million in Ethereum within 48 hoursJune 2, 2023 | msn.comRocket Lab delays its Venus atmospheric probe missionJune 1, 2023 | msn.comRocket Lab’s private mission to Venus slips to 2025June 1, 2023 | detroitnews.comEMBARGO: Rocket's housing stability initiative returns to in-person canvassingJune 1, 2023 | detroitnews.comYoung gun Tom Kim, fan favorite Max Homa returning to Rocket Mortgage ClassicJune 1, 2023 | msn.comPoarch Creek Indians donate $2.5 million to Space & Rocket CenterMay 31, 2023 | forbes.comG2 Esports Reveals All-Women ‘Rocket League’ Team For North AmericaMay 31, 2023 | msn.comJimmy Butler a Rocket? Houston offered four first-round picks to Minnesota but was turned downMay 31, 2023 | markets.businessinsider.comRocket Pharma Says EMA Grants PRIME Designation For RP-A501 Gene Therapy For Danon DiseaseMay 31, 2023 | finance.yahoo.comRocket Pharmaceuticals Receives European Medicines Agency (EMA) Priority Medicines (PRIME) Designation for RP-A501 Gene Therapy for Danon DiseaseSee More Headlines RCKT Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart RCKT Company Calendar Last Earnings5/04/2023Today6/08/2023Next Earnings (Estimated)8/14/2023Fiscal Year End12/31/2023Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:RCKT CUSIPN/A CIK1281895 Webwww.rocketpharma.com Phone(609) 659-8001Fax646-224-9585Employees151Year Founded2018Price Target and Rating Average Stock Price Forecast$51.09 High Stock Price Forecast$75.00 Low Stock Price Forecast$34.00 Forecasted Upside/Downside+117.8%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage12 Analysts Profitability EPS (Most Recent Fiscal Year)($3.35) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-221,860,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-55.70% Return on Assets-49.53% Debt Debt-to-Equity Ratio0.04 Current Ratio10.83 Quick Ratio10.83 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$6.47 per share Price / Book3.63Miscellaneous Outstanding Shares80,461,000Free Float55,438,000Market Cap$1.89 billion OptionableOptionable Beta1.22 Social Links Key ExecutivesGaurav D. ShahChief Executive Officer & DirectorKinnari PatelPresident & Chief Operating OfficerJohn C. MilitelloTreasurer, Chief Financial & Accounting OfficerMayo PujolsChief Technical Officer & Executive Vice PresidentMark WhiteChief Medical OfficerKey CompetitorsBELLUS HealthNASDAQ:BLUSupernus PharmaceuticalsNASDAQ:SUPNGeronNASDAQ:GERNFibroGenNASDAQ:FGENPacira BioSciencesNASDAQ:PCRXView All CompetitorsInsiders & InstitutionsProShare Advisors LLCSold 1,102 shares on 5/26/2023Ownership: 0.015%Putnam Investments LLCBought 406,514 shares on 5/22/2023Ownership: 0.781%JPMorgan Chase & Co.Sold 26,046 shares on 5/18/2023Ownership: 1.021%New York State Common Retirement FundSold 4,983 shares on 5/18/2023Ownership: 0.036%Rockefeller Capital Management L.P.Bought 21,000 shares on 5/17/2023Ownership: 0.085%View All Insider TransactionsView All Institutional Transactions RCKT Stock - Frequently Asked Questions Should I buy or sell Rocket Pharmaceuticals stock right now? 12 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Rocket Pharmaceuticals in the last twelve months. There are currently 12 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" RCKT shares. View RCKT analyst ratings or view top-rated stocks. What is Rocket Pharmaceuticals' stock price forecast for 2023? 12 analysts have issued 12-month price objectives for Rocket Pharmaceuticals' stock. Their RCKT share price forecasts range from $34.00 to $75.00. On average, they predict the company's share price to reach $51.09 in the next twelve months. This suggests a possible upside of 117.8% from the stock's current price. View analysts price targets for RCKT or view top-rated stocks among Wall Street analysts. How have RCKT shares performed in 2023? Rocket Pharmaceuticals' stock was trading at $19.57 at the beginning of 2023. Since then, RCKT shares have increased by 19.9% and is now trading at $23.46. View the best growth stocks for 2023 here. When is Rocket Pharmaceuticals' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Monday, August 14th 2023. View our RCKT earnings forecast. How were Rocket Pharmaceuticals' earnings last quarter? Rocket Pharmaceuticals, Inc. (NASDAQ:RCKT) issued its quarterly earnings results on Thursday, May, 4th. The biotechnology company reported ($0.73) EPS for the quarter, beating the consensus estimate of ($0.84) by $0.11. During the same period in the previous year, the business earned ($0.67) EPS. What ETFs hold Rocket Pharmaceuticals' stock? ETFs with the largest weight of Rocket Pharmaceuticals (NASDAQ:RCKT) stock in their portfolio include Global X Genomics & Biotechnology ETF (GNOM), Global X Guru Index ETF (GURU), Harbor Health Care ETF (MEDI), ALPS Medical Breakthroughs ETF (SBIO), Harbor Disruptive Innovation ETF (INNO), Putnam BioRevolution ETF (SYNB), SPDR S&P Biotech ETF (XBI) and Virtus LifeSci Biotech Clinical Trials ETF (BBC). What other stocks do shareholders of Rocket Pharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some companies that other Rocket Pharmaceuticals investors own include Nymox Pharmaceutical (NYMX), Pfizer (PFE), SCYNEXIS (SCYX), Sorrento Therapeutics (SRNE), Amarin (AMRN), Energy Transfer (ET), Micron Technology (MU), VBI Vaccines (VBIV), Vaxart (VXRT) and Alibaba Group (BABA). What is Rocket Pharmaceuticals' stock symbol? Rocket Pharmaceuticals trades on the NASDAQ under the ticker symbol "RCKT." Who are Rocket Pharmaceuticals' major shareholders? Rocket Pharmaceuticals' stock is owned by many different institutional and retail investors. Top institutional shareholders include BlackRock Inc. (6.79%), Maverick Capital Ltd. (5.48%), Wellington Management Group LLP (5.11%), State Street Corp (5.00%), Westfield Capital Management Co. LP (4.02%) and Price T Rowe Associates Inc. MD (2.32%). Insiders that own company stock include Gaurav Shah, Gotham Makker, John Militello, Jonathan David Schwartz, Kinnari Patel and Rtw Investments, Lp. View institutional ownership trends. How do I buy shares of Rocket Pharmaceuticals? Shares of RCKT stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is Rocket Pharmaceuticals' stock price today? One share of RCKT stock can currently be purchased for approximately $23.46. How much money does Rocket Pharmaceuticals make? Rocket Pharmaceuticals (NASDAQ:RCKT) has a market capitalization of $1.89 billion. The biotechnology company earns $-221,860,000.00 in net income (profit) each year or ($3.35) on an earnings per share basis. How many employees does Rocket Pharmaceuticals have? The company employs 151 workers across the globe. How can I contact Rocket Pharmaceuticals? Rocket Pharmaceuticals' mailing address is 350 FIFTH AVENUE SUITE 7530, NEW YORK NY, 10118. The official website for the company is www.rocketpharma.com. The biotechnology company can be reached via phone at (609) 659-8001, via email at investors@rocketpharma.com, or via fax at 646-224-9585. This page (NASDAQ:RCKT) was last updated on 6/9/2023 by MarketBeat.com Staff Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Rocket Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.